Round-up Archives - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Round-up

January’s top news stories

Eli Lilly signed a definitive agreement to acquire biopharmaceutical firm Dermira for approximately $1.1bn in cash, and Sumitomo Dainippon Pharma and Exscientia advanced their first joint drug candidate, DSP-1181, into clinical development. Pharmaceutical-technology.com wraps up...

November’s top news stories

November’s top news stories

Novartis has signed a definitive agreement to acquire The Medicines Company for a total consideration of $9.7bn, and China’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers. Pharmaceutical-technology.com wraps up key headlines from November 2019.

October’s top news stories

October’s top news stories

UCB has signed a merger agreement to acquire Ra Pharmaceuticals for $48 per share, totalling $2.1bn in cash, and Novartis has allied with Microsoft to leverage the latter’s AI technology for the discovery, development and commercialisation of medicines. Pharmaceutical-technology.com wraps up key headlines from October 2019.

August’s top news stories

August’s top news stories

Bayer has signed an agreement to acquire US-based biotechnology company BlueRock Therapeutics for $1bn, and The World Health Organization (WHO) has claimed that malaria can be eradicated with accelerated research and development (R&D), using new tools. Pharmaceutical-technology.com wraps up key headlines from August 2019.

July’s top news stories

July’s top news stories

Zirabev gets FDA approval to treat five types of cancer and Dundee University and Bukwang to develop Parkinson’s drug. Pharmaceutical-technology.com wraps up key headlines from June 2019.

May’s top news stories

Takeda to divest dry eye drug to Novartis in $5.3bn deal Takeda Pharmaceutical signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up…

April’s top news stories

Novartis to buy IFM Tre for up to $1.57bn Novartis agreed to acquire anti-inflammatory group IFM Tre, a subsidiary of IFM Therapeutics, in a deal worth up to $1.57bn. Under…

February’s top news stories

Top pharma executives testify before US Senate over high prices Top executives from seven major pharmaceutical companies have appeared before the US Finance Committee to testify about the high prices of…

January’s top news stories

BMS acquires Celgene for an equity value of $74bn Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an…